Italy parties seek way out of election stalemate


ROME (Reuters) - Italy's stunned political parties searched for a way forward on Tuesday after an inconclusive election gave none of them a parliamentary majority and threatened prolonged instability and a renewal of the European financial crisis.


The results, notably the dramatic surge of the anti-establishment 5-Star Movement of comic Beppe Grillo, left the center-left bloc with a majority in the lower house but without the numbers to control the upper chamber, the Senate.


Financial markets fell sharply at the prospect of a stalemate that reawakened memories of the crisis that pushed Italy's borrowing costs toward unsustainably high levels and brought the euro zone to the brink of collapse in 2011.


"The winner is: Ingovernability," ran the headline in Rome newspaper Il Messaggero, reflecting the deadlock the country will have to confront in the next few weeks as sworn enemies are forced to work together to form a government.


Ratings agency Standard & Poor's said on Tuesday that policy choices of the next Italian government would be crucial for the country's creditworthiness, underlining the need for a coalition that can agree on new reforms.


Pier Luigi Bersani, head of the center-left Democratic Party (PD), has the difficult task of trying to agree a "grand coalition" with former prime minister Silvio Berlusconi, the man he blames for ruining Italy, or striking a deal with Grillo, a completely unknown quantity in conventional politics.


The alternative is new elections either immediately or within a few months, although both Berlusconi and Bersani have indicated that they want to avoid a return to the polls if possible: "Italy cannot be ungoverned and we have to reflect," Berlusconi said in an interview on his own television station.


For his part, Grillo, whose movement won the most votes of any single party, has indicated that he believes the next government will last no more than six months.


"They won't be able to govern," he told reporters on Tuesday. "Whether I'm there or not, they won't be able govern."


He said he would work with anyone who supported his policy proposals, which range from anti-corruption measures to green-tinted energy measures but rejected suggestions of entering a formal coalition: "It's not time to talk of alliances... the system has already fallen," he said.


The election, a massive rejection of the austerity policies applied by Prime Minister Mario Monti with the backing of international leaders from U.S. President Barack Obama to German Chancellor Angela Merkel, caused consternation across Europe.


German Finance Minister Wolfgang Schaeuble put a brave face on it, saying "that's democracy".


Spanish Foreign Minister Jose Manuel Garcia-Margallo was more pessimistic.


"This is a jump to nowhere that does not bode well either for Italy or Europe," he said.


A long recession and growing disillusionment with mainstream parties and tax-raising austerity fed a bitter public mood and contributed to the massive rejection of Monti, whose centrist coalition was relegated to the sidelines.


Projections by the Italian center for Electoral Studies showed that the center-left will have 121 seats in the Senate, against 117 for the center-right alliance of Berlusconi's PDL and the regionalist Northern League. Grillo would take 54.


That leaves no party with the majority in a chamber which a government must control to pass legislation.


"THE BELL IS RINGING"


On a visit to Germany, President Giorgio Napolitano said he would not comment until the parties had consulted with each other and Bersani called on Berlusconi and Grillo to "assume their responsibilities" to ensure Italy could have a government.


He warned that the election showed austerity policies alone were no answer to the economic crisis and said the result carried implications beyond Italy.


"The bell is ringing for Europe as well," he said in his first public comments since the election.


He said he would present a limited number of reform proposals to parliament, focusing on jobs, institutional reform and European policy.


However forming an alliance may be long and difficult and could test the sometimes fragile internal unity of the mainstream parties.


"The idea of a majority without Grillo is unthinkable. I don't know if anyone in the PD is considering it but I'm against it," said Matteo Orfini, a member of Bersani's PD secretariat.


"The idea of a PD-PDL government, even if it's backed by Monti, doesn't make any sense," he said.


For his part, Berlusconi won a boost when his Northern League ally Roberto Maroni won the election to become regional president of Lombardy, Italy's economic heartland and one of the richest and most productive areas of Europe.


For Italian business, with an illustrious history of export success, the election result brought dismay that there would be no quick change to what they see as a regulatory sclerosis that has kept the economy virtually stagnant for a decade.


"This is probably the worst possible scenario," said Francesco Divella, whose family began selling pasta under its eponymous brand in 1890 in the southern region of Puglia.


Berlusconi's campaign, mixing sweeping tax cut pledges with relentless attacks on Monti and Merkel, echoed many of the themes pushed by Grillo and underlined the increasingly angry mood of the Italian electorate.


But even if the next government turns away from the tax hikes and spending cuts brought in by Monti, it will struggle to revive an economy that has scarcely grown in two decades.


Monti was widely credited with tightening Italy's public finances and restoring its international credibility after the scandal-plagued Berlusconi, who is currently on trial for having sex with an under-age prostitute.


However, Monti struggled to pass the kind of structural reforms needed to improve competitiveness and lay the foundations for a return to economic growth. A weak center-left government may not find it any easier.


The view from some voters, weary of the mainstream parties, was unrepentant: "It's good," said Roger Manica, 28, a security guard in Rome, who voted for the center-left PD.


"Next time I'll vote 5-Star. I like that they are changing things, even if it means uncertainty. Uncertainty doesn't matter to me, for me what's important is a good person who gets things done," he said. "Look how well they've done."


(Additional reporting by Barry Moody, Gavin Jones, Lisa Jucca, Steven Jewkes, Steve Scherer, Catherine Hornby and Massimiliano Di Giorgio, Annika Breidthardt in Berlin. Writing by Philip Pullella and James Mackenzie; Editing by Peter Graff)



Read More..

gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-









Title Post: gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Url Post: http://www.news.fluser.com/gn2wzw-%df%a3%e9%90%a8q%ca%adl-q-xmjvu0ryut%de%8fh-eta%d5%adk84bkuf1dvbgywpz%d6%ac-%cc%b2%d7%9bjvx8gnew%c8%89p%c9%95u%da%8cmkf%cb%b2-o%c9%ab%d8%a97v6umeua%cd%b4/
Link To Post : gN2WZW ߣ鐨qʭl q$ :}X,MjVư&0ryUŤޏh, %Et]Aխk#8>4b;KuF1dV@BgyWpZ֬>+ ̲כ#Jv@X8Gň(/EwȉPɕ]Uڌ+mkf˲-+oɫة7>v6ume\Uaʹё(NϢ؈co#е/]5eA{zG1�-/F% 2ɮ6,dיcq! F+3jZ|lZ Xo;y-RvOb_?;OTxi-!O2z롸/Mdf’,@@_OoT;o O$Ǩ64`%Y/h93m&(gJc>S:”N5kExD!Kzf1|M+’X{fu6E݌ 3>.`#Ĩ?Sӌ!c8ʴ)|}R8ѥ)Ncݥdx,iA]w0″L)f|. qN{91؜TWiEO:5`c4ȉ21ԵEH”DŽYt; mp=*a܆y’ԙ>AU?a=LypBL,sŖB”C]Ӧj悌fyn0t?)dD,>”䕙s$ s{tir’.L,3Ui՜FeZu 4Mho&1Ja퍾8u>TY%*:dMvm@R/O(xJ竔ךH 37MqXq,yJ2; G6e\p*)w9=3nӗ|d1+i3En?4jfDgh,7 3|!ew_Mv4N4+a8ņlxf{nO[e C Dw9CX&(.KdZtIhn3Ѷz8rC!`\9~EV/ءaIy EI兗ŽA 4Lc_G]-
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Bobby Brown Sentenced to 55 Days in Jail in Drunk Driving Case















02/26/2013 at 09:30 PM EST



Bobby Brown has been sentenced to 55 days in jail and four years probation in his most recent drunk driving arrest.

Brown, 44, was pulled over in Studio City, Calif., on Oct. 24 for driving erratically and was arrested when the officer detected "a strong scent of alcohol." He was charged with DUI and driving on a suspended license.

He was also arrested for driving under the influence in March of 2012.

Brown pled no contest to the charges on Tuesday, reports TMZ. He was also ordered to complete an 18-month alcohol treatment program.

The singer, who married Alicia Etheredge in Hawaii in June of 2012, must report to jail by March 20.

Read More..

Tegra 4 performance crushes current-gen processors







NVIDIA’s (NVDA) next-generation processors won’t be available in devices until later this year, however early benchmarks have revealed that the new chipset will be worth the wait. Engadget ran a variety of benchmark tests on one of the company’s Tegra 4 reference tablets and was left with scores that in some cases nearly quadrupled the performance of older Tegra 3 devices.


[More from BGR: Samsung is just trolling us now, and it’s not alone]






 Tegra 4 performance crushes current gen processors


[More from BGR: Another major security flaw discovered on iPhone [video]]


Tegra 4 Quadrant scores topped out at 16,436 and AnTuTu benchmarks reached over 36,000, both of which more than tripled the performance from comparable Tegra 3 tablets. Perhaps the most impressive result was the 499ms score from the SunSpider test. The Tegra 4 benchmark, which measures web browsing performance, nearly halved Apple’s iPad 4 score of 865ms.


NVIDIA and its partners are scheduled to debut Tegra 4 in smartphones, tablets and the company’s Project Shield gaming device in July.


This article was originally published on BGR.com


Gadgets News Headlines – Yahoo! News





Title Post: Tegra 4 performance crushes current-gen processors
Url Post: http://www.news.fluser.com/tegra-4-performance-crushes-current-gen-processors/
Link To Post : Tegra 4 performance crushes current-gen processors
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

The Bachelor's Sean Lowe Reveals Final Two






The Bachelor










02/25/2013 at 10:30 PM EST







From left: AshLee, Lindsay and Catherine


Kevin Foley/ABC(3)


And then there were two.

After three incredible dates in Thailand with the remaining women, The Bachelor's Sean Lowe faced a difficult decision at the end of Monday's episode: Would he send home AshLee, Catherine or Lindsay?

Keep reading to find out who got a rose – and who was left heartbroken ...

Sean said goodbye to early favorite AshLee in a surprising elimination that left her virtually speechless.

Visibly upset, AshLee left Sean's side without saying goodbye. She even asked him to not walk her to the waiting car that would take her away.

But Sean did get to explain. "I thought it was you from the very beginning," he said. "This was honestly the hardest decision I've ever had to make ... I think the world of you. I did not want to hurt you."

"This wasn't a silly game for me," AshLee said as the car drove away. "This wasn't about a joy ride. It wasn't about laughing and joking and having fun."

She added: "It's hard to say goodbye to Sean because I let him in ... It's the ultimate [rejection]."

Check back Tuesday morning for Sean Lowe's blog post to read all about his Thailand dates and why he chose to send AshLee home

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Firefox takes on smartphone powers Apple, Google






SAN FRANCISCO (Reuters) – Mozilla, makers of the popular Firefox Internet browser, is preparing to challenge Google and Apple‘s grip on smartphone software.


A new Firefox operating system for mobile devices is set for a July release after winning the backing of 13 wireless service providers around the globe, including Spain’s Telefonica, China Unicom and America Movil.






Mozilla is betting there’s room for a software developer-friendly mobile platform alongside Apple’s and Google’s Android, which together power the majority of mobile devices on the planet.


The new software is based on open Web standards and is capable of operating on devices with much lower hardware requirements than today’s existing crop of smarpthones, according to Mozilla.


Because the Firefox OS is open-source and Web-based, third-party developers will be free to sell mobile applications without needing to share revenue with Apple or Google.


“There’s a strategic imperative for the industry to have another OS that really is open and supports choice and competition,” said Mozilla’s Senior Vice President of Products, Jay Sullivan.


Mozilla will showcase some of the first hardware devices based on that software at the Mobile World Congress, taking place in Barcelona this week. Among the brands that have signed on to make devices based on Firefox OS are South Korea’s LG, China’s ZTE and Huawei.


Unlike Google and Apple’s operating systems, which are built from proprietary technology, Firefox OS uses the HTML5 standard that Web services are built with. That means anyone familiar with Web programming can create Firefox OS apps.


Whether a smartphone built on Web standards can deliver the kind of performance that consumers expect remains to be seen. Facebook famously stopped using HTML5 to develop its iPhone app last year, with Chief Executive Mark Zuckerberg saying the technology couldn’t deliver acceptable quality and calling a decision to use HTML5 for its app one of Facebook’s “biggest mistakes.”


SIZE MATTERS


Mozilla, a non-profit organization, also faces stiff competition. Google’s Android software, which the company distributes free to phone vendors from Samsung to HTC, had roughly 70 percent share of the worldwide smartphone market in the fourth quarter, according to industry research firm Gartner. Apple, which created the smartphone market with the 2007 launch of the now-iconic iPhone, had a roughly 21 percent share of the market.


“The real barrier here is not necessarily a technical one, it’s scale,” said John Jackson, an analyst with research firm IDC. Mozilla will need to attract large numbers of consumers and app developers if it hopes to avoid the fate of previous mobile operating system hopefuls, such as Palm’s WebOS, now owned by Hewllet-Packard.


But “the world’s computing experiences are going mobile and when they get to the mobile environment, they’re happening on a platform that’s controlled by either Apple or Google,” said Jackson. “There’s a universe of content and service providers that have an interest in seeing a more neutral platform materialize.”


Mozilla will initially look to compete in so-called “emerging economies” in Latin America, Eastern Europe and Asia, where many people still use older phone models and have yet to upgrade to more expensive smartphones that feature touchscreens and high-speed Internet connections.


The first phones will be available this summer in Brazil, Columbia, Poland, Venezuela, Serbia and Spain.


The first Firefox OS phones that Telefonica will offer this summer come with a wholesale price of $ 100. The price that consumers pay for the phone will vary in different markets and depend on whether the phone is offered on a pre-paid basis or comes with a service contract, a Telefonica spokesman said.


Telefonica will eventually offer higher-end Firefox OS phones, and plans to offer Firefox devices in all 25 countries that it operates in by the end of 2014.


(Reporting By Alexei Oreskovic; Editing by Bernard Orr)


Linux/Open Source News Headlines – Yahoo! News





Title Post: Firefox takes on smartphone powers Apple, Google
Url Post: http://www.news.fluser.com/firefox-takes-on-smartphone-powers-apple-google/
Link To Post : Firefox takes on smartphone powers Apple, Google
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Jennifer Lawrence Falls - But Shakes It Off - and Wins Best Actress









02/25/2013 at 12:50 AM EST







Jennifer Lawrence accepts the Best Actress Oscar


Kevin Winter/Getty


It was perhaps the most unpredictable moment of the Oscars Sunday night when Jennifer Lawrence made her way to the stage to accept her Oscar for Best Actress for her role in Silver Linings Playbook on Sunday.

The 22-year-old actress slipped on the stairs but luckily her full skirted Dior Haute Couture gown cushioned her fall.

After she slipped, gentleman Hugh Jackman was spotted rushing to aid if necessary. "I had to help her, poor thing! I didn't know if she could get up," he told PEOPLE after the show.

Lawrence was unfazed: "Thank you!" she began as she stood at the podium clutching her award. "You guys are just standing up 'cause you feel bad that I fell and that's really embarrassing, but thank you."

She continued: "This is nuts! Thank you to the Academy and thank you to the women this year, you were so magnificent. You were so inspiring and not just those of you in my category; and it's been so amazing getting to know you and you've been so nice and you've made this experience unforgettable."

While thanking her team, family and fellow cast members, Lawrence even managed to sneak in a birthday shootout to French actress (and fellow Best Actress nominee) Emmanuelle Riva who turned 86 on Sunday.

But after the awards show had ended, Lawrence remained in good spirits about her slip. Backstage in the press room, she joked first that she had done it on purpose and then quipped that someone had "waxed the stairs."

It's been a whirlwind awards season for Lawrence who also won a Screen Actors Guild Award and Golden Globe.

– With Reporting by Julie Jordan and Elizabeth Leonard

Jennifer Lawrence Falls – But Shakes It Off – and Wins Best Actress| Academy Awards, Oscars 2013, Jennifer Lawrence

Lawrence in Dior

Kevin Winter / Getty

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.


Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.


Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.


"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.


Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.


But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.


National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.


"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.


OPTIONS BULLS TARGET GAINS


The spending cuts, if they go ahead, could hit the defense industry particularly hard.


Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.


Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.


"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.


The stock ended up 0.6 percent at $88.12 on Friday.


If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.


General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.


EYES ON GDP DATA, APPLE


The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.


U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.


Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.


Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.


On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.


(Additional reporting by Doris Frankel; Editing by Kenneth Barry)



Read More..